While new disease management solutions are hitting the market every day, chronic disease rates are still rising in the United States. Our country sees $3.8 trillion in healthcare costs each year, and chronic diseases are currently the leading cause of death and disability.
Digital technology has the potential to play an impactful role in chronic disease management by improving patient engagement and therapy adherence, as well as empowering healthcare providers with better insights to deliver more personalized care in real time.
Given the challenges and trends surrounding chronic disease management, it's more important than ever for innovators to have a platform they can rely on as they create new digital health solutions. That's where BrightInsight comes in.
Diabetes management is complex and often frustrating for patients and care teams. Novo Nordisk selected the BrightInsight Platform to capture data from its next-generation connected insulin pens and integrate data from leading third-party diabetes solutions, including the Abbott Freestyle Libre system, the Glooko Diasend platform, the Dexcom continuous blood glucose meters, and diabetes solutions from Roche.
Novo’s non-exclusive partnership strategy is incredibly unique in an industry where data is historically very siloed. By safely and securely enabling data integration across Novo Nordisk’s partner ecosystem, the BrightInsight Platform supports Novo Nordisk’s goals of helping more people realize the full benefit of their innovative medicines and beginning to ease the burden of diabetes management for those individuals.
If you're ready to improve patient outcomes while driving care delivery efficiencies for patients with chronic conditions, then it's time to start leveraging our platform. We can help you:
You can learn more about how we can help you innovate by checking out our Novo Nordisk case study.